Pharma Bio Debt
| PBSV Stock | USD 0.50 0.05 9.09% |
Pharma Bio Serv holds a debt-to-equity ratio of 0.032. . Pharma Bio's financial risk is the risk to Pharma Bio stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Pharma Bio's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Pharma Bio's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Pharma OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Pharma Bio's stakeholders.
For most companies, including Pharma Bio, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Pharma Bio Serv, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Pharma Bio's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Pharma Bio's debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Pharma Bio is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Pharma Bio to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Pharma Bio is said to be less leveraged. If creditors hold a majority of Pharma Bio's assets, the OTC Stock is said to be highly leveraged.
Pharma |
Pharma Bio Serv Debt to Cash Allocation
Many companies such as Pharma Bio, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Pharma Bio Serv currently holds 520.77 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Pharma Bio Serv has a current ratio of 8.89, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Pharma Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Pharma Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharma Bio Serv sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharma to invest in growth at high rates of return. When we think about Pharma Bio's use of debt, we should always consider it together with cash and equity.Pharma Bio Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Pharma Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Pharma Bio, which in turn will lower the firm's financial flexibility.Pharma Bio Corporate Bonds Issued
Understaning Pharma Bio Use of Financial Leverage
Understanding the structure of Pharma Bio's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Pharma Bio's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico. Pharma Bio operates under Health Information Services classification in the United States and is traded on OTC Exchange. It employs 190 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pharma OTC Stock Analysis
When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.